Document Detail


Anemia in multiple myeloma.
MedLine Citation:
PMID:  16163188     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Anemia is a common complication in patients with multiple myeloma (MM) and occurs in more than two thirds of all patients. The most frequent underlying pathophysiological mechanism is anemia of chronic disease (ACD), relative erythropoietin (EPO) deficiency (due partly to renal impairment) and myelosuppressive effects of chemotherapy, but many other factors may account for or contribute to anemia in myeloma. In patients who achieve complete remission after chemotherapy, anemia usually normalizes. Nonresponders and relapsing myeloma patients often continue to suffer from anemia. Treatment options for anemic myeloma patients include red blood cell (RBC) transfusions and recombinant human erythropoietin (rHuEPO). Red blood cell transfusions convey an immediate effect and rapidly increase the patient's hemoglobin level. Unfortunately, effects of RBC transfusions are only transient and can be associated with several risks, including infections and mild to even life-threatening immunologic reactions. rHuEPO is biologically equivalent to the human endogenous hormone EPO, and its application leads to an increase of hemoglobin levels over an extended time without the risks of blood transfusions. Several studies reported a significant improvement of erythropoiesis, reduction in transfusion need, and improved quality of life by using rHuEPO as long-term treatment of myeloma-associated anemia. Recently, an international expert panel recommended the use of rHuEPO for anemic myeloma patients where other possible causes of anemia have been eliminated.
Authors:
Heinz Ludwig; Gudrun Pohl; Anders Osterborg
Related Documents :
3965308 - Characteristics of menstruation in sickle cell disease.
7123148 - Influence of residual splenic tissue on the presence of vacuolated erythrocytes in sple...
1245948 - Transfusion therapy for cerebrovascular abnormalities in sickle cell disease.
8866138 - Experience with the port-a-cath in sickle cell disease.
15641938 - Intima media thickness of common carotid arteries is associated with traditional risk f...
22391068 - The role of nitrosative stress in the pathogenesis of unexplained chronic cough with co...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical advances in hematology & oncology : H&O     Volume:  2     ISSN:  1543-0790     ISO Abbreviation:  Clin Adv Hematol Oncol     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2005-09-15     Completed Date:  2007-09-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  101167661     Medline TA:  Clin Adv Hematol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  233-41     Citation Subset:  IM    
Affiliation:
Department of Medicine I, Wilhelminenspital, Vienna, Austria. heinz.ludwig@wienkav.at
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia / drug therapy,  etiology*,  physiopathology,  prevention & control,  therapy
Blood Transfusion / adverse effects
Cell Hypoxia
Clinical Trials as Topic / statistics & numerical data
Erythropoietin, Recombinant / adverse effects,  therapeutic use
Fatigue / etiology
Humans
Models, Biological
Multiple Myeloma / blood,  complications*
Neovascularization, Pathologic / etiology,  physiopathology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Erythropoietin, Recombinant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen...
Next Document:  Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed c...